Rybelsus, the first oral GLP-1 receptor agonist approved for managing type 2 diabetes, has garnered significant attention for its role in lowering blood sugar levels. Users appreciate its convenience compared to injectable alternatives. It works by enhancing insulin secretion and reducing glucagon release, which collectively assist in maintaining stable glucose…